Health Insurance (Section 3C General Medical Services – Extracorporeal Photopheresis for Chronic Graft Versus Host Disease) Determination 2022

Key legal concepts in this Determination are: the treatment of a specified health service as a medical and professional service for the purposes of the Health Insurance Act framework (s 5); the specification of discrete MBS items in the Schedule (Schedule); clinical eligibility and service delivery conditions that gate access to the items (Schedule items 13761 and 13762); incorporation of existing general medical services table clauses so that their rules apply to the new items (s 6, s 8); definitions of treatment cycle and treatment session as operational units for entitlement and claiming (s 7); a formulaic indexation of fees at a specified indexation time (s 9); and a cross‑reference regime for statutory text and other Acts and regulations as they operate from time to time (s 4(2)).

Treatment as a “relevant service” , the instrument adopts the mechanics of subsection 3C(1) of the Act by specifying that relevant services in the Schedule are to be treated, for the relevant provisions, as if they were both professional and medical services and as if there were items in the general medical services table specifying a fee per State (s 5). This importation links the Schedule items to the administrative apparatus that governs Medicare benefit entitlements, claiming, and provider responsibilities under the Health Insurance Act and associated regulations. The instrument also defines “relevant provisions” to include provisions of the Act and regulations and the National Health Act 1953 and its regulations, that relate to medical services, professional services or items (s 4(1)). That cross‑referencing means the items do not stand alone; they are embedded in the existing regulatory matrix.

Clinical and delivery gatekeeping. The Schedule spells out multiple eligibility and delivery conditions: prior receipt of allogeneic haematopoietic stem cell transplant; diagnosis of chronic GVHD; unsuitability of steroid therapy in defined ways; prior response for subsequent cycles; mandatory use of an integrated, closed ECP system; co‑administration with methoxsalen listed on the Pharmaceutical Benefits Scheme; and provision by or on behalf of a haematology or oncology specialist with allogeneic bone marrow transplantation experience (Schedule). These are cumulative prerequisites for the items.

Session and cycle units. The Determination defines a treatment cycle as a period of 12 weeks commencing on the start date of treatment, and a treatment session as a single ECP treatment within a cycle (s 7). The items are payable “once per treatment session (H)”, which fixes the claim frequency and links each payment to a single session within a 12‑week cycle (Schedule).

Indexation mechanics. Section 9 prescribes a single indexation event at the start of 1 July 2025, applying a multiplier of 1.024 to each fee and rounding to the nearest 5 cents (s 9(1)‑(3)). The instrument notes that indexed fees could be viewed on the Department’s MBS Online website, signalling administrative publication and future visibility.

Incorporation into general medical services table clauses. Clauses 1.2.7 and 1.2.11 are to have effect as if the new items were specified in those clauses (s 6). Clause 1.2.9, clause 1.2.10 and clause 5.1.1 are to have effect as if the new items were specified in those clauses (s 8(1)‑(3)). The Determination thereby places the new items under the existing substantive restrictions and operational prescriptions contained in those clauses, though the text of those clauses is not reproduced in this instrument.

Cross‑statutory references. The instrument defines its references to provisions of the Act and the National Health Act as references to the provisions “as in force from time to time” (s 4(2)). That means future statutory or regulatory changes to the referenced instruments will affect the operation of the items where the reference operates to specify a matter.

Together, these concepts create narrowly framed, administratively integrated MBS items that rely on clinical, device, drug, and provider conditions, operate on a session/cycle basis, and are embedded into the existing rules and restrictions of the general medical services table.

Primary affected parties

• Patients with chronic graft versus host disease: The Schedule restricts item eligibility to people who have received allogeneic haematopoietic stem cell transplantation and subsequently been diagnosed with chronic GVHD, and who meet additional clinical conditions (Schedule, items 13761, 13762). Those meeting the criteria may have access to Medicare‑reimbursed ECP sessions subject to the Determination’s conditions (s 5; Schedule).
• Specialists and consultant physicians in haematology or oncology: Both items require the service to be provided by, or on behalf of, a specialist or consultant physician practising in haematology or oncology with experience in allogeneic bone marrow transplantation (Schedule). This restricts the class of practitioners who can authorise or be responsible for claiming the item.
• ECP clinics and hospital units providing extracorporeal photopheresis: The Determination makes eligibility conditional on delivery with an “integrated, closed extracorporeal photopheresis system” (Schedule). Clinics or providers that use open systems or different devices will not satisfy that condition and therefore cannot claim the items unless they change equipment or procurement.

Payers and funders

• Medicare (the Australian Government through the Health Insurance Act machinery): By treating the specified services as medical and professional services and as items in the general medical services table (s 5), the Determination brings the services within the namespace of services for which Medicare benefits are administered and paid under the relevant provisions. The immediate fiscal cost will be to government programmes that administer medical benefits according to the Act and regulations.
• Patients’ out‑of‑pocket position and private insurers: The instrument fixes a fee per session (Schedule: $1,908.35) which defines the MBS fee baseline. The relationship between that fee and actual charged fees, gap amounts, and private health insurer coverage is not set out in this instrument. Clinics, hospitals and specialists will make choices about billing practices, gap charges and private health insurance claims; those decisions determine direct patient expenditure.

Regulatory and administrative actors

• Department of Health and Aged Care / MBS administrators: The Determination references publication of indexed fees on the Department’s MBS Online website (s 9 note). Administrative systems will need to code the new items, validate clinical prerequisites at claims processing, and enforce the restrictions imported by reference.
• Pharmaceutical Benefits Scheme administration: Eligibility requires the use of methoxsalen that is listed on the Pharmaceutical Benefits Scheme (Schedule). Changes to PBS listing status for methoxsalen will directly affect item applicability.

Indirectly affected parties and markets

• Manufacturers and suppliers of integrated, closed ECP systems: The device requirement concentrates demand on suppliers of integrated, closed systems, since use of such systems is a precondition of the items (Schedule). That may affect purchasing decisions by hospitals and specialist clinics.
• Suppliers of methoxsalen: Because treatment must be provided in combination with methoxsalen that is PBS‑listed (Schedule), methoxsalen suppliers and PBS pricing decisions influence access and cost structure.
• Competing therapy providers and referral pathways: Clinicians and hospitals providing alternative treatments for chronic GVHD will face potential substitution effects if ECP becomes more accessible under Medicare for patients meeting the conditions.

Scope and exclusions

• Patients previously treated with ECP: Item 13761 applies only to persons who have not previously received ECP; item 13762 addresses subsequent cycles but requires prior partial or complete response in at least one organ (Schedule). Patients who do not meet these history or response criteria cannot access these items.
• Situations excluded by other GMS restrictions: Section 8(4) provides that an item in the Schedule does not apply if the service is associated with a service to which an item in Group A3 or Group A4 of the general medical service tables applies. That exclusion will matter to patients receiving other listed attendances, depending on the content of Group A3/A4 items.

In short, the Determination affects a narrow clinical population and a defined set of providers and device/drug suppliers, and shifts cost and billing consequences onto Medicare’s benefits framework while imposing technical delivery and eligibility gates that influence procurement, clinical decision‑making and billing practice.

Statutory treatment and entitlements

• Right to be treated as a medical/professional service for relevant provisions: Under s 5, a relevant service provided in accordance with the instrument and as a clinically relevant service “is to be treated, for the relevant provisions, as if” it were both a professional and medical service and as if there were a corresponding item in the general medical services table with the fee specified in the Schedule. This creates the statutory basis for benefit entitlement and claiming under the Health Insurance Act framework for compliant services.
• Right to claim once per treatment session: The Schedule states each item is “Applicable once per treatment session (H)”. That fixes the unit of benefit entitlement as a single ECP session within the treatment cycle (Schedule).

Provider duties and conditions

• Specialist involvement: Both items require that the service “is provided by, or on behalf of, a specialist or consultant physician” who meets the specialty and experience criteria (Schedule). Providers therefore have a duty to satisfy, document and, where necessary, evidence the practitioner’s specialty and experience in allogeneic bone marrow transplantation when the service is claimed.
• Device and drug preconditions: The service must be delivered using an integrated, closed ECP system and in combination with methoxsalen that is listed on the Pharmaceutical Benefits Scheme (Schedule). Providers have a duty to ensure the device and pharmaceutical co‑requirements are met for the item to be available.
• Treatment history and response documentation: For item 13761, the person must not have previously received ECP; for item 13762, the person must have previously received an ECP treatment cycle and had a partial or complete response in at least one organ (Schedule). Providers must record treatment history and response to justify claims under the items.

Incorporated duties from general medical services table

• Where the Determination directs that particular clauses of the general medical services table “shall have effect as if the items contained in the Schedule of the Determination were also specified in the clause” (s 6, s 8(1)‑(3)), the duties, restrictions, and requirements in those clauses become applicable to the new items. The instrument does not reproduce those clauses; providers must consult the general medical services table to identify and comply with duties that will apply by incorporation (s 6; s 8).

Indexation and administrative obligations

• Fee indexation: The Determination prescribes a one‑off indexation at 1 July 2025 using a multiplier of 1.024 and rounding rules (s 9). Administrators and claimants will need to use the indexed fee from that date and follow MBS Online for published indexed amounts.

Restrictions on concurrent claiming

• Non‑application with Group A3 or A4 services: Section 8(4) provides that an item in the Schedule does not apply to a service if it is associated with a service to which an item in Group A3 or Group A4 applies. This creates a duty to assess billing combinations and to withhold claims where association with those grouped services would displace the Schedule item’s applicability.

Rights to Medicare benefit

• The Determination creates a statutory pathway to Medicare reimbursement for ECP sessions that meet the instrument’s cumulative conditions. The provider or person eligible to claim benefit has the right to seek the MBS benefit subject to compliance with the Act, regulations, and the incorporated clauses of the general medical services table (s 5; s 4(1)).

Operational implications

• The instrument allocates decision responsibilities to providers to ensure clinical eligibility, device and drug combinations, and specialist involvement are fulfilled. Administrative decision‑making on claims will be exercised by Medicare administrators consistent with the Act and the general medical services table provisions incorporated by reference. Providers therefore carry the primary compliance burden in establishing entitlement to the item.

Statutory enforcement framework

• Enforcement and penalties for misuse or non‑compliance with items in the general medical services table are governed by the “relevant provisions” of the Health Insurance Act 1973 and regulations and the National Health Act 1953 and regulations, as incorporated by the Determination (s 4(1); s 5). The Determination itself does not create specific penalties; it imports the Act’s enforcement regime by treating the items as if present in the general medical services table.

Delegation of enforcement to administrators

• Medicare claims for these items will be processed under the usual administrative procedures applicable to general medical services table items. That includes claims validation, audit, and potential recovery actions administered by the Department of Health and Aged Care or its delegates under the Health Insurance Act and regulations. The Determination prescribes the content and conditions of the item; enforcement will be by the same agencies and mechanisms that enforce other MBS items.

Potential consequences for incorrect claims

• Because the instrument treats the services as if they were items in the general medical services table (s 5), submitting claims that do not meet the Schedule’s conditions risks administrative recovery of benefits improperly paid, and other penalties that the Act and regulations provide for non‑compliant billing. Specific sanctions under the Act may include debt recovery, suspension from Medicare claiming, and other regulatory responses available under the Health Insurance Act and related instruments. The Determination does not itself modify or specify those sanctions.

Audit and documentation expectations

• The item conditions include clinical history requirements (prior transplant, diagnosis of chronic GVHD, steroid unsuitability or prior response) and device/drug requirements (integrated closed system; methoxsalen listed on PBS). These conditions create an evidential expectation: providers will need contemporaneous clinical records and procurement documentation sufficient to demonstrate compliance on audit. Failure to produce records consistent with the Schedule’s conditions will expose claimed benefits to challenge and potential recovery.

Interaction with PBS listing

• The requirement that methoxsalen be “listed on the Pharmaceutical Benefits Scheme” ties item eligibility to PBS administrative decisions. If a methoxsalen listing were to be removed, the item’s eligibility condition would no longer be satisfied and claims based on the service in combination with a non‑PBS methoxsalen could be vulnerable to being rejected or recovered.

No special criminal penalties in the instrument

• The Determination does not create new criminal offences or specify novel penalty structures; enforcement will be through existing administrative and civil mechanisms available under the Health Insurance Act and related legislation. Providers should therefore treat the instrument’s conditions as mandatory eligibility gates subject to the Act’s general enforcement mechanisms.

Practical enforcement risk

• The instrument’s cumulative and technical eligibility criteria concentrate enforcement risk on billing accuracy, clinical documentation and device/drug procurement. Providers face a compliance cost in documenting and evidencing eligibility; those who cannot demonstrate compliance face regular administrative enforcement outcomes under the Act.

Relationship with the Health Insurance Act 1973

• The Determination is made under subsection 3C(1) of the Health Insurance Act 1973 (s 3). Section 5 of the Determination expressly directs that, for the purposes of subsection 3C(1), a relevant service provided in accordance with the instrument is to be treated, for the “relevant provisions”, as though it were both a professional service and a medical service and as if there were an item in the general medical services table specifying a fee for each State (s 5). This places the Schedule items squarely within the administrative and legal framework of the Health Insurance Act, making the normal provisions governing MBS items and Medicare benefits applicable.

Interaction with the National Health Act 1953 and the Pharmaceutical Benefits Scheme

• The Determination defines “Pharmaceutical Benefits Scheme” as the scheme established under Part VII of the National Health Act 1953 and requires that services be provided in combination with methoxsalen that is listed on the PBS (s 4(1); Schedule). This creates a direct operational nexus between MBS item eligibility and PBS listing status. Changes to Part VII PBS listings may therefore affect the Determination’s operation for individual patients or drugs.

Incorporation of general medical services table clauses

• Sections 6 and 8 operate by reference to the general medical services table, specifying that clauses 1.2.7, 1.2.11, 1.2.9, 1.2.10 and 5.1.1 are to have effect as if the new items were also specified in those clauses (s 6; s 8(1)‑(3)). The Determination therefore imports the content and restrictions of those clauses into the operational legal context of the new items. Practitioners and administrators must consult the current text of the general medical services table to determine the precise duties, exclusions and conditions that are thereby applied.

References to provisions “as in force from time to time”

• Section 4(2) states that a reference in this instrument to a provision of the Act or the National Health Act 1953 or their regulations is a reference to those provisions “as in force from time to time” where the reference operates to specify a matter. That means future amendments to the Health Insurance Act, the National Health Act or their regulations may change the way the Determination operates, for example altering the content of incorporated clauses or the mechanics of claims and penalties.

Overlap and exclusion with Group A3 and Group A4 items

• Section 8(4) provides that an item in the Schedule does not apply to a service if it is associated with a service to which an item in Group A3 or Group A4 of the general medical service tables applies. This cross‑provision creates an interactional rule with other parts of the general medical services table that may operate to exclude the ECP items from application in certain clinical combinations. Determination users must consult the general medical services table for the content of Groups A3 and A4 to understand concrete consequences.

Administrative publication and indexing

• Section 9 includes a note that indexed fees could be viewed on the Department of Health and Aged Care’s MBS Online website and prescribes an indexation event at 1 July 2025 using a multiplier of 1.024 with specified rounding (s 9). Administrative interaction therefore includes publication obligations and dependence on the Department’s systems to communicate updated fees.

No displacement of other regulatory controls

• The Determination does not repeal or displace other legal or regulatory controls applicable to clinical practice or hospital operation, such as state hospital licensing, prostheses lists, pathology or imaging regulation, or PBS prescribing requirements. The instrument explicitly ties into, but does not replace, existing federal frameworks (s 4(1)). Providers must therefore observe intersecting legal requirements beyond the Determination itself.

In short, the Determination functions within the Health Insurance Act architecture, imports and is subject to the general medical services table clauses by reference, conditions eligibility on PBS listing, and is responsive to future statutory and regulatory change by adopting “as in force from time to time” references. Administrative reliance on MBS Online for publication of indexed fees is also defined.

Instrument origin and status

• The Determination identifies itself by name as the Health Insurance (Section 3C General Medical Services - Extracorporeal Photopheresis for Chronic Graft Versus Host Disease) Determination 2022 (s 1 Name). The instrument is made under subsection 3C(1) of the Health Insurance Act 1973 (s 3 Authority).

No amendments recorded within the text

• The instrument as provided contains no express amendment clauses or schedules that modify earlier Determinations. It does not indicate prior versions or contain internal amendment history notes. The instrument’s text itself does not record any prior amendments or revocations.

Indexation scheduled for 2025

• The only temporal modification explicitly provided is the indexation mechanism in s 9, which will replace each item fee at the start of 1 July 2025 using a multiplier of 1.024 and rounding rules (s 9(1)‑(3)). That acts as a future, single‑event modification to the Schedule fees, not as an open amendment process.

Monitoring for future amendments

• Section 4(2) makes references to provisions of the Act and the National Health Act “as in force from time to time” where those references specify a matter. That clause anticipates and incorporates subsequent legislative or regulatory amendments that affect the referenced provisions. Practitioners should therefore monitor the Health Insurance Act, the National Health Act and the MBS general medical services table for future amendments that will affect this Determination’s operation.

Administrative publication

• The instrument notes that indexed fees could be viewed on MBS Online (s 9 note). Practically, the Department of Health and Aged Care’s MBS Online is the binding administrative publication channel for the operational text, updates and potential amendments affecting items and fees. Users should monitor MBS Online for any formal amending instruments or notices.

No recorded legislative amendments in this document

• The provided Determination contains no amendment schedule or historical note of prior versions. If an amendment history exists outside this text, it would be recorded in the Federal Register of Legislation or on the Department’s administrative pages. The Determination itself therefore appears, from the provided text, as a standalone instrument enacted in 2022 with a scheduled indexation event in 2025.

Practical implication

• Absent further published amending instruments, practitioners and administrators should treat the Determination as current and rely on the Schedule, the statutory incorporation of general medical services table clauses, and the indexation event. They should also ensure they have processes to check the Federal Register of Legislation and MBS Online for any future legislative or administrative changes that modify this Determination’s scope, fees or operational rules.

No litigation recorded in the instrument

• The Determination itself contains no references to case law, judicial interpretation, or any litigation history. The instrument does not name any cases and does not contain footnotes or explanatory material citing judicial decisions.

Implication for practice

• Because the instrument is a technical statutory instrument prescribing MBS items and conditions, any litigation that might arise in future would likely be administrative in nature (for example disputes over eligibility, benefit recovery, or interpretation of incorporated general medical services table clauses) and would be litigated under the Health Insurance Act and related administrative law processes. The Determination contains no material that indicates such litigation has occurred or been considered at the time it was made.

How to locate litigation if it arises

• Practitioners should monitor Federal Court, Federal Circuit and Family Court, and Administrative Appeals Tribunal decisions for judicial interpretation of these items, and should check legal databases and MBS Online for guidance or administrative determinations. The instrument’s “as in force from time to time” references (s 4(2)) mean that subsequent legislative changes or administrative clarifications may reduce or increase the likelihood of litigation over particular elements, such as the meaning of “integrated, closed extracorporeal photopheresis system” or what constitutes sufficient evidence of prior response in at least one organ.

No precedent named in the text

• The Determination does not reference prior MBS decisions, determinations, or administrative rulings. For questions of interpretation of the incorporated clauses of the general medical services table (clauses 1.2.7, 1.2.9, 1.2.10, 1.2.11 and 5.1.1), relevant administrative or judicial decisions concerning those clauses (if any) would inform interpretation, but such materials are not cited here.

Recommendation

• Given the potential for disputes about claim validity under tight eligibility rules, providers and legal advisers should establish recordkeeping systems to document clinical prerequisites, device and drug usage, and clinician qualifications. Absent existing litigation, careful compliance documentation is the principal hedge against administrative dispute and potential proceedings under the Health Insurance Act’s enforcement mechanisms.

Narrow cumulative eligibility criteria

• The Schedule attaches multiple cumulative prerequisites. For item 13761, a person must have had an allogeneic haematopoietic stem cell transplant, be diagnosed with chronic GVHD, be steroid refractory/dependent/intolerant (so steroid is clinically unsuitable), and must not have previously received ECP (Schedule, item 13761). For item 13762, prior receipt of an ECP treatment cycle with a partial or complete response in at least one organ is required before further ECP is claimable (Schedule, item 13762). Missing documentation or differences in clinical interpretation on any single element can render a claim non‑compliant.

Device definition and procurement risk

• The requirement that the service be delivered using an “integrated, closed extracorporeal photopheresis system” is precise. Providers using non‑integrated or open systems will not meet the condition as written. The Determination does not define “integrated, closed” within its text; clinics must therefore interpret that phrase conservatively or seek administrative guidance to avoid rejected claims or recoveries. Device procurement decisions will directly affect eligibility.

Drug listing dependency

• The requirement that the service be provided in combination with methoxsalen that is listed on the Pharmaceutical Benefits Scheme creates a dependency on PBS listing status. If methoxsalen were delisted or unavailable under PBS, the items could not be lawfully applied per the instrument. Providers must ensure the exact formulation and listing status match the PBS entry at the time of treatment.

“Provided by, or on behalf of” drafting

• The Schedule permits the service to be provided “by, or on behalf of” a qualifying specialist or consultant physician (Schedule). That phrase allows delegation but raises evidentiary questions on audit: administrators may require proof that the service was delivered under appropriate clinical supervision or responsibility. Providers should maintain formal delegation or supervision records to substantiate “on behalf of” arrangements.

Treatment history evidentiary requirements

• For item 13762 the service is only available if a prior treatment cycle yielded a partial or complete response in at least one organ. That raises potential ambiguity about the clinical criteria for “partial or complete response” and how it is documented. Insufficient clinical detail in records could risk claim challenges.

Claiming frequency and cycle definition

• The Determination defines a treatment cycle as extending over 12 weeks from the start date and a treatment session as a single ECP treatment in that series (s 7). Administratively, providers must track cycles and sessions precisely to avoid over‑claiming. The term “Applicable once per treatment session (H)” fixes the claiming unit but may interact with other MBS items; s 8(4) excludes application where services are associated with Group A3 or A4 items, so attention to concurrent attendances is necessary.

Interaction with unspecified GMS clauses

• Sections 6 and 8 import the effect of several general medical services table clauses as if the items were specified in those clauses. The Determination does not reproduce those clauses. Practitioners who do not consult the current GMS table may miss substantive duties, restrictions or billing rules that apply to the new items by incorporation.

Indexation rounding and timing

• The indexation multiplier in s 9(1) is 1.024 applied at the start of 1 July 2025 and rounded to the nearest 5 cents (s 9(1)‑(3)). Fee calculation and rounding can cause minor differences in per‑session entitlement; administrative systems and billing staff should update fee schedules and ensure correct rounded fees are used from the stated indexation time.

Exclusion with Group A3/A4 services

• Section 8(4) nullifies applicability where a service is associated with services to which Group A3 or A4 items apply. Without checking the content of Group A3 and A4 items, providers risk unintended disqualification of the ECP item or duplicative billing. Verify the content of those groups before finalising billing strategies.

Operational gap between MBS fee and provider charge

• The Schedule sets a fee of $1,908.35 per session as the MBS item fee. The Determination does not cap provider charges or regulate gap fees, and it does not state that the MBS fee is the total payable amount. Providers should confirm their own billing policies and understand how private health insurers and patient gap arrangements will interact with the MBS fee.

No express transitional provisions for ongoing cycles

• The instrument does not state transitional arrangements for patients mid‑treatment at the Determination’s commencement. Providers should check administrative guidance or seek advice about transitional treatment cycles that began before the Determination came into force.

Clinical gatekeeping and documentation

• Confirm clinical eligibility before each claimed session. For a first course (item 13761), document: (a) the record of allogeneic haematopoietic stem cell transplantation; (b) diagnosis of chronic GVHD; (c) clinical reasoning and evidence that steroid treatment is clinically unsuitable because disease is steroid refractory, steroid dependent or steroid intolerant; and (d) confirmation that the patient has not previously received ECP. For subsequent cycles (item 13762), document: (a) prior ECP treatment cycle dates; (b) evidence of partial or complete response in at least one organ; and (c) clinical rationale for further ECP. These documentary elements are explicit preconditions in the Schedule and will be central in claims validation (Schedule).

Device and drug compliance

• Ensure the ECP session is delivered using an integrated, closed extracorporeal photopheresis system. Maintain procurement, maintenance and device specifications on file as part of the clinical record to evidence compliance. Also ensure methoxsalen used in conjunction with the ECP session is the formulation listed on the Pharmaceutical Benefits Scheme at the time of treatment and keep PBS dispensing records or relevant invoices linked to the treatment episode (Schedule).

Provider qualification and delegation

• The service must be provided by, or on behalf of, a specialist or consultant physician practising haematology or oncology with experience in allogeneic bone marrow transplantation. If services are delivered by allied health, nursing staff, or less‑senior medical officers on behalf of the specialist, document the supervision arrangement, the responsible specialist’s involvement and oversight, and the specialist’s qualifications and experience. The “by, or on behalf of” language allows delegation but requires evidentiary support for that delegation (Schedule).

Coding and claiming practice

• Code claims to items 13761 and 13762 as applicable, treating each claimed payment as “once per treatment session (H)” and ensuring the session falls within a treatment cycle as defined (s 7; Schedule). Update billing systems to reflect the item numbers and the current per‑session fee. Be prepared to apply the indexed fee from 1 July 2025 using the multiplier 1.024 and the rounding rule specified in s 9(1)‑(3).

Manage interactions with other MBS items

• Before claiming, verify that the ECP service is not associated with a service to which an item in Group A3 or Group A4 applies, because s 8(4) displaces the Schedule item in that case. Consult the general medical services table to understand how the incorporated clauses in s 6 and s 8 affect allowable combinations and other claims rules.

Recordkeeping and audit preparedness

• Keep contemporaneous clinical notes that explicitly state the patient’s transplant history, GVHD diagnosis, steroid suitability assessment, prior ECP response where relevant, device used, methoxsalen PBS listing and dose, and the specialist’s role. Retain procurement and device maintenance records to evidence use of an integrated, closed ECP system. Good documentation reduces the risk of claims recovery and administrative penalties under the Health Insurance Act’s enforcement mechanisms.

Monitor PBS and MBS Online changes

• Because eligibility depends on PBS listing for methoxsalen and the Determination references provisions “as in force from time to time” (s 4(2)), maintain processes to check the PBS schedule and MBS Online regularly for changes that affect item applicability, PBS listings, or general medical services table clause content. Implement administrative triggers to update clinical practice and billing when the PBS or GMS text changes.

Establish internal compliance checks

• Implement a pre‑claim sign‑off process requiring the responsible specialist to certify that the treatment meets the Schedule’s conditions. Use checklists for the clinical prerequisites, device type, PBS drug, and prior response evidence for subsequent cycles. Train billing staff in the specific item definitions and the exclusion with Group A3/A4 items.

Pricing and gap management

• Decide on gap‑charging practice in advance. The Determination sets the MBS fee; it does not fix patient out‑of‑pocket obligations or regulate private insurer interactions. Providers should document fee schedules and compute gaps accurately so patients receive clear financial information before treatment.

Interface with institutional policies

• Hospital administrators and clinics should align procurement and clinical governance policies to ensure equipment meets the “integrated, closed” requirement, specialists with the specified experience are available, and recording practices are standardised. Ensure that credentialing processes for specialists explicitly document necessary experience in allogeneic bone marrow transplantation.

Seek administrative clarification when needed

• Where text is ambiguous, for example the precise meaning of “integrated, closed extracorporeal photopheresis system” or the clinical threshold for “partial response”, seek written guidance from the Department of Health and Aged Care or use MBS Online resources. Administrative clarification reduces audit risk.

By implementing these processes and maintaining continuous monitoring of legal and administrative changes, providers can align clinical practice and claiming behaviour with the Determination’s conditions, reducing compliance risk and ensuring lawful access to Medicare benefits for eligible ECP sessions.